A 38-year-old man with moderate persistent asthma presents to the outpatient clinic. He has been using salbutamol inhaler 4–5 times per week for the past 3 months. Spirometry shows FEV₁ 65% of predicted. He denies nocturnal symptoms or exercise limitation. What is the most appropriate next step in management?

Explanation

## Clinical Assessment This patient meets criteria for **moderate persistent asthma** (symptoms 3–4 days per week, FEV₁ 60–80% predicted, GINA Step 2–3). Current management with SABA monotherapy is inadequate. ## Stepwise Asthma Management (GINA) | Step | Criteria | Controller Drug | |------|----------|------------------| | Step 1 | Intermittent symptoms | SABA PRN only | | Step 2 | Mild persistent (≥2 days/week) | **ICS monotherapy (low dose)** | | Step 3 | Moderate persistent (daily symptoms) | ICS + LABA or medium-dose ICS | | Step 4 | Severe persistent (continuous) | High-dose ICS + LABA ± LTRA/theophylline | | Step 5 | Inadequate control on Step 4 | Biologic agents (omalizumab, mepolizumab) | **Key Point:** This patient has **≥2 days/week** symptom frequency (using SABA 4–5 times/week) and reduced FEV₁, placing him at **Step 2–3 boundary**. The most appropriate next step is initiation of **ICS monotherapy at low-to-medium dose**, as per GINA guidelines [cite:GINA 2023]. ## Why ICS Monotherapy First? **High-Yield:** ICS is the gold standard anti-inflammatory agent for persistent asthma. Starting with ICS monotherapy allows assessment of response before escalating to ICS + LABA combination, which is reserved for inadequate control on medium-dose ICS (Step 3). **Clinical Pearl:** LABA should **never** be used as monotherapy — always combined with ICS due to increased risk of asthma-related deaths when used alone [cite:KD Tripathi 8e Ch 29]. ## Management Algorithm ```mermaid flowchart TD A[Moderate persistent asthma<br/>FEV₁ 60-80%, symptoms 3-4 days/week]:::outcome A --> B{Current control adequate?}:::decision B -->|No - on SABA alone| C[Initiate ICS low-to-medium dose]:::action C --> D{Response after 4 weeks?}:::decision D -->|Good| E[Continue ICS monotherapy]:::outcome D -->|Inadequate| F[Escalate to ICS + LABA]:::action F --> G[Reassess at 4 weeks]:::decision ```